You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Nimesulide
Nimesulide is a selective, orally active cyclooxygenase-2 (COX-2) inhibitor. Produces potent analgesic, anti-inflammatory and antipyretic activities in vivo. Reported to produce fewer gastrointestinal side effects than standard NSAIDs. Also inhibits sodium-dependent neutral amino acid transporter B0AT1 (SLC6A19; IC50 = 23 μM).
Technical Data for Nimesulide
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Nimesulide
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Nimesulide
The following data is based on the product molecular weight 308.31. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.24 mL||16.22 mL||32.43 mL|
|5 mM||0.65 mL||3.24 mL||6.49 mL|
|10 mM||0.32 mL||1.62 mL||3.24 mL|
|50 mM||0.06 mL||0.32 mL||0.65 mL|
References for Nimesulide
References are publications that support the biological activity of the product.
Famaey (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm.Res. 46 437 PMID: 9427063
Cullen et al (1998) Selective cyclooxygenase-2 inhibition by nimesulide in man. J.Pharmacol.Exp.Ther. 287 578 PMID: 9808683
Pochini et al (2014) Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter. Mechanism of inhibition revealed by proteoliposome transport assay and molecular modelling. Biochem.Pharmacol. 89 422 PMID: 24704252
If you know of a relevant reference for Nimesulide, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Nimesulide, Nimesulide supplier, Cyclooxygenase-2, COX-2, inhibitors, inhibits, Cyclooxygenase, Oxygenases, Oxidases, B0AT1, SLC6A19, sodium-dependent, neutral, amino, acid, transporter, Flogovital, Aulin, Other, Ion, Pumps/Transporters, 2470, Tocris Bioscience
3 Citations for Nimesulide
Citations are publications that use Tocris products. Selected citations for Nimesulide include:
Staniaszek et al (2010) Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids. Br J Pharmacol 160 669 PMID: 20590570
Baranowska-Kuczko et al (2014) Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries. J Neuroimmune Pharmacol 387 477 PMID: 24682422
Anneken et al (2013) MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase. Nat Commun 8 58 PMID: 23179355
Do you know of a great paper that uses Nimesulide from Tocris? Please let us know.
Reviews for Nimesulide
There are currently no reviews for this product. Be the first to review Nimesulide and earn rewards!
Have you used Nimesulide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.